Considerations on Development of New Chinese Medicine Drug in Medical Institutions

Luo Lina, Chen Gengxin

Chinese Pharmaceutical Affairs ›› 2022, Vol. 36 ›› Issue (3) : 251-255.

Chinese Pharmaceutical Affairs ›› 2022, Vol. 36 ›› Issue (3) : 251-255. DOI: 10.16153/j.1002-7777.2022.03.002
Supervision Administration

Considerations on Development of New Chinese Medicine Drug in Medical Institutions

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2022, 36(3): 251-255 https://doi.org/10.16153/j.1002-7777.2022.03.002

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-4
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉